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Background: Artemisinin combination therapy (ACT) is recommended as first-line treatment for uncomplicated
Plasmodium falciparum malaria, whereas chloroquine is still commonly used for the treatment of non-falciparum
species (Plasmodium vivax, Plasmodium ovale and Plasmodium malariae). A more simplified, more uniform treatment
approach across all malaria species is worthwhile to be considered both in endemic areas and for malaria as an
imported condition alike.
Methods: A PROSPERO-registered systematic review to determine the efficacy and safety of ACT for the treatment
of non-falciparum malaria was conducted, following PRISMA guidelines. Without language restrictions, Medline/
PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, LILACS, Biosis Previews and the
African Index Medicus were searched for studies published up to November 2014.
Results: The literature search identified 986 reports; 40 publications were found eligible for inclusion, all of them on
non-falciparum malaria in endemic areas. Most evidence was available for P. vivax (n = 35). Five clinical trials in total
were identified evaluating ACT for P. ovale, P. malariae and Plasmodium knowlesi. Most ACT presentations have high
efficacy against P. vivax parasites; artemisinin-based combinations have shorter parasite and fever clearance times
compared to chloroquine. ACT is as effective as chloroquine in preventing recurrent parasitaemia before day 28.
Artemisinin-based combinations with long half-lives show significantly fewer recurrent parasitaemia up to day 63.
The limited evidence available supports both the use of chloroquine and an ACT for P. ovale and P. malariae. ACT
seems to be preferable for optimal treatment of P. knowlesi.
Conclusion: ACT is at least equivalent to chloroquine in effectively treating non-falciparum malaria. These findings
may facilitate development of simplified protocols for treating all forms of malaria with ACT, including returning
travellers. Obtaining comprehensive efficacy and safety data on ACT use for non-falciparum species particularly for
P. ovale, P. malariae and P. knowlesi should be a research priority.
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Malaria remains one of the most important and poten-
tially life-threatening parasitic diseases of humans. Five
species of the genus Plasmodium are known to cause
human malaria infections. The majority of cases are
caused by Plasmodium falciparum, which can lead to high
morbidity and mortality if not treated promptly. Non-
falciparum malaria is caused by Plasmodium vivax,
Plasmodium ovale subspecies, Plasmodium malariae
or Plasmodium knowlesi. Data on the epidemiological
patterns of the non-falciparum malarias is scarce. In Asia
and the Americas, where malaria transmission is generally
low and seasonal, P. falciparum and P. vivax malaria have
nearly the same prevalence. Plasmodium malariae and P.
ovale are mainly found in sub-Saharan Africa and comprise
<10% of isolates. Currently, non-falciparum malaria consti-
tutes approximately 25% of all annually imported 11,000
cases of malaria in Europe [1-3]. Artemisinin combination
therapy (ACT) is recommended as first-line treatment
for uncomplicated falciparum malaria [4]. It is considered
for traveller’s malaria and P. knowlesi in endemic areas,
whereas chloroquine (CQ) is still the standard drug for
P. vivax, P. malariae and P. ovale in most countries [5].
The different treatment recommendations for P. falcip-
arum and non-falciparum malaria may have several
drawbacks in clinical practice. Most importantly, mis-
classification of Plasmodium spp. is common especially
where non-falciparum infections are involved, due to
lack of training in microscopy and variations in morpho-
logical characteristics within and between Plasmodium
spp. [6,7]. CQ treatment of misclassified P. falciparum
can have severe or even fatal consequences due to wide-
spread CQ resistance of P. falciparum. Despite internal
and external quality assessments for parasitological diag-
nosis, discrepant results between microscopy and poly-
merase chain reaction (PCR) can still occur even in
experienced laboratories [8]. Besides, mixed species
infections are common [9] and microscopic diagnosis of
mixed-species infections is particularly cumbersome
[10,11]. Rapid diagnostic tests (such as the NOW® ICT
MALARIA P.f/P.v. test based on P. falciparum HRP2/
aldolase), are not capable to differentiate safely single
species P. falciparum infection from concurrent P.
malariae or P. ovale [12]. Those tests fail probably
because of the small quantities of antigen circulating due
to a low parasitaemia in P. malariae and P. ovale. An
evaluation of three rapid diagnostic test (OptiMAL-IT,
BinaxNOW® Malaria and Paramax-3) for the detection
of P. knowlesi infection demonstrated a low sensitivity
(OptiMAL-IT 71%, BinaxNOW® 29% and Paramax-3
RDT 40% for fresh P. knowlesi samples) and low specifi-
city and a risk of misdiagnosis of P. falciparum or vivax
[13]. Although PCR can unambiguously differentiate
between subspecies, it is not used in routine clinical care.Secondly, P. vivax resistance to CQ is emerging in
parts of sub-Saharan Africa and South East Asia [14]. A
recent meta-analysis to establish the global extent of
chloroquine resistance showed chloroquine resistance in
58 (53%) of 113 assessable study sites, spread across
most countries that are endemic for P. vivax [15]. The
World Health Organization (WHO) recommends the
use of ACT also for the treatment of P. vivax in affected
areas [16]. So far, resistance of P. ovale and P. malariae
to CQ has been reported only once from Indonesia [17].
Finally, intake of CQ is unpopular in many African
descendants due to frequently experienced side effects,
e.g. pruritus [8] due to CQ’s affinity to melanocytes [18].
Artemisinin derivatives are generally well tolerated, and
the safety profile of ACT may be by-and-large deter-
mined by the partner drug [19]. The clinical impact of
non-falciparum malaria infection seems to be more
important as it was considered the last three decades.
A systematic review and meta-analysis showed P.
vivax as a major cause of severe malaria and a com-
parable incidence of severe malaria between P. vivax
and P. falciparum was found in infants, children and
adults [20].
Hence, there might be a compelling rationale to treat
all (including returning travellers) diagnosed with mal-
aria with an ACT irrespective of malaria species [21].
More or less identical first-line treatments based on
ACT for all malaria species would not only simplify
treatment schemes and avoid ineffective CQ treatment
of unrecognized P. falciparum infection, but also offer
logistical benefits in terms of pharmacological manage-
ment, whilst the need to eliminate P.vivax/P.ovale hyp-
nozoites outside endemic areas has to be accounted for.
Moreover, using a combination treatment will less likely
result in artemisinin resistance development. However,
certainty about the efficacy and safety of ACT for
non-falciparum malaria and mixed malaria infections
is needed before translating ACT treatment for all
malaria infections into practice. This review aims at
describing the efficacy and safety of ACT for non-
falciparum malaria.
The overall objective of the review was to summarize
available data on efficacy and safety of artemisinin
combination therapy (ACT) for the treatment of non-
falciparum malaria. Primary endpoint was to describe
the cure rate at day 28; secondary endpoints were to
describe cure rates at days 0–3, 7, 14, 21, 28, 42, 56
and 63, fever clearance time (FCT), parasite clearance
time (PCT) and adverse events profiles [22].
Methods
This review was conducted in June 2014. The last search
was conducted on 16 November 2014. Objectives
and inclusion criteria were specified in advance and
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the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) group were followed
[23]. This review was registered in advance in PROS-
PERO (International prospective register of systematic
reviews). Registration number: CRD42014009103 [24].
The full methods section is described in Additional
file 1. For the search strategy and selection criteria,
see Additional file 2.
Results
The initial search yielded 2,022 records of which 986
remained after removal of duplicates (see PRISMA flow
diagram, Figure 1). Forty records met the inclusion
criteria. Of these, n = 35 for P. vivax malaria and n = 5
altogether for P. malariae, P. ovale or P. knowlesi con-
tained the necessary data for the qualitative synthesis.
The full text was retrievable for all included recordsFigure 1 PRISMA flow diagram. From: Moher D, Liberati A, Tetzlaff J, Altm
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6except two [25,26]. No study for the treatment of trav-
ellers with non-falciparum malaria with ACT in non-
endemic high-income countries was identified.
Treatment of Plasmodium vivax malaria
The epidemiology, clinical presentation and diagnosis of
P. vivax are not in the scope of this review and have
been covered elsewhere [27].
ACT versus CQ
Fifteen randomized clinical trials (Table 1) compared
ACT with CQ monotherapy (with or without pri-
maquine (PQ); the studied artemisinin-based combi-
nations were artemether-lumefantrine (AL) [28-32],
dihydroartemisinin-piperaquine (DHA + PP) [33-35],
artesunate plus sulphadoxine-pyrimethamine (AS + SP)
[36-38], artesunate-pyronaridine (AS + PY) [39], artemi
sinin-naphtoquine (AN) [40], or artesunate (AS) [41]an DG, The PRISMA Group (2009). Preferred Reporting Items for
: e1000097.
Table 1 Clinical trials of varying design that specifically report on the effectiveness of an artemisinin derivate combin with a blood schizonticide for the































DHA + PP (2) 32 8 h 16 h NR NR NR NR NR NR 91% NR NR Day 42: P = 0.62





AN (3) 127 26.0 h 26.9 h 80.3% 80.3% 100% NR NR 100% 98.4% NR NR Day 42: p = 0.4496
CQ + PQ (3 + 8) 128 37.4 h 39.8 h 40.6% 54.7% 100% NR NR 100% 96.1% NR NR
Leang et al. 2013
[33]β
Cambodia CCT DHA + PP 168 NR NR 85.5% 100% 100% NR NR 100% NR NR NR NR







167 <48 h NR NR 100% NR NR NR NR 91% NR NR Day 42: p = 0.51
DHA + PP + PQ
(3 + 14)





AS (6) 41 <72 h NR NR NR 100% 100% 100% 39,0% NR NR NR NR
DHA + PP + PQ
(3 + 14)
39 <72 h NR NR NR 94.9% 100% 100% 100% NR NR NR





AL (3) 114 NR NR NR 100% 100% NR NR 91.1% 58.8% NR NR Day 2: p = 0.006
CQ (3) 107 NR NR NR 94% 99,1% NR NR 97,2% 68.4% NR NR Day 28: p = 0.003
Senn et al. 2013
[45]α
Papua New Guinea CT AL (NR) 594 NR NR NR NR NR 99.8% NR 97.8% 88% NR NR NR
Mohapatra et al.
2013 [41] NR
India CT AS (7) 60 48.2 h 47.8 h NR NR NR NR NR 96.6% NR NR NR NR
Barber et al.
2013 [46] NA
Malaysian Borneo CT AL + PQ (+AS) 43 48 h 24 h NR NR NR NR NR NR NR NR NR NR
Abdallah et al.
2012 [47]α
Sudan CT AL + PQ (3 + 14) 38 NR NR 94.7% 100% NR NR NR 100% NR NR NR NR
Eibach et al.
2012 [32]β

















Table 1 Clinical trials of varying design that specifically report on the effectiveness of an artemisinin derivate combin with a blood schizonticide for the
treatment of Plasmodium vivax, P. malariae, P. ovale or P. knowlesi malaria (Continued)
Phyo et al. 2011
[34]α
Thailand RCT DHA + PP (3) 248 NR NR 63,7% 97,5% 100% NR NR 95,9% NR NR 45.1% Day 1: p < 0.001
CQ(3) 244 NR NR 21,1% 84,1% 97.9% NR NR 90.2% NR NR 20.9% Day 2: p < 0.001
Day 28: p = 0.032





RCT, Phase III AS + PY (3) + PQ 228 23.0 h 15,9 h NR NR NR NR 99.5% NR NR NR NR PCT: p < 0.0001
FCT: p = 0.0017
CQ (3) 228 32.0 h 23,8 h NR NR NR NR 100% NR NR NR NR
Difference (95% CI)
Day 14: −0.5 (−2,6-1,4)
Yohannes et al.
2011 [29]α
Ethiopia CCT AL (3) 88 NR NR NR NR NR NR NR 81.0% NR NR NR Day 28: p = 0.0145
CQ (3) 71 NR NR NR NR NR NR NR 92.5% NR NR NR




DHA + PP (3) 264 NR NR 91.3% 97.8% NR NR NR 100% NR 97.2% NR Day 1: p < 0.001
CQ (3) 266 NR NR 78.9% 97.0% 99,2% NR NR 100% NR 91.1% NR Day 2: p = 0.59
Day 56: p = 0.003
PiDan et al. 2009
[25] (abstract only)
China CT AS (5) 30 16.3 h 38.3 h NR NR NR NR NR NR NR NR NR Cure rate: 53,3% (AS) vs.
56.7% (AH). Day: NR
AH (3) 30 23.8 h 38.5 h
Krudsood et al.
2008 [53]β
Thailand RCT (1)AS + PQ
(5 + 5)
68 34.9 h 16.8 h NR NR NR NR NR 85% NR NR NR Group 1 ≠ group 4 and
group 5 (p = 0.004 and
0.003). Group 2≠ group
4 and group 5 (p = 0.015
and 0.014)
(2) AS + PQ
(5 + 7)
69 36.0 h 20.0 h NR NR NR NR NR 89% NR NR NR
(3) AS + PQ
(5 + 9)
66 35.7 h 14.5 h NR NR NR NR NR 96% NR NR NR
(4) AS + PQ
(5 + 11)
64 34.2 h 13.8 h NR NR NR NR NR 100% NR NR NR
(5) AS + PQ
(5 + 14)
66 37.2 h 19.6 h NR NR NR NR NR 100% NR NR NR
(6) AS + PQ (5 + 7)
double dose PQ
















Table 1 Clinical trials of varying design that specifically report on the effectiveness of an artemisinin derivate combined with a blood schizonticide for the
treatment of Plasmodium vivax, P. malariae, P. ovale or P. knowlesi malaria (Continued)
Karunajeewa
et al. 2008 [38]β
Papua New Guinea RCT AL (3) 39 1.4d 2.1d NR NR NR NR NR 55.5% 45.5% NR NR PCT: ACTs vs.
CQ + SP: p = 0.05
AS + SP (3) 51 1.1d 2.1d NR NR NR NR NR 63.8% 51.3% NR NR FCT: p > 0.05
DHA + PP (3) 44 1.2d 1.9d NR NR NR NR NR 84.2% 72.2% NR NR
CQ + SP (3) 61 3.1d 2.3d NR NR NR NR NR 58.8% 44.7% NR NR
Dao et al. 2007
[42]β
Vietnam CT AS + PQ (2 + 7) 28 14.2 h 18.6 h NR NR NR NR NR 96.2% NR NR NR NR
Hasugian et al. 2007
[54]α
Papua, Indonesia RCT AAQ + PQ
(3 + 14)
75 <48 h <48 h NR NR NR NR NR NR 52% NR NR Day 42: p < 0.001
DHA + PP + PQ
(3 + 14)
74 <48 h <48 h NR NR NR NR NR NR 84% NR NR
Ratcliff et al.
2007 [55]α
Papua, Indonesia RCT AL (3) 141 NR NR NR NR NR NR NR NR 43% NR NR p < 0.0001
DHA + PP (3) 147 NR NR NR NR NR NR NR NR 86% NR NR
Krudsood et al.
2007 [31]α
Thailand RCT AL + PQ (3 + 14) 47 41.6 h 21.8 h NR NR NR NR NR 97.4% NR NR NR PCT: p < 0.001
FCT: p = 0.12
CQ + PQ (3 + 14) 51 55.8 h 25.3 h NR NR NR NR NR 100% NR NR NR
Kolaczinski et al.
2007 [36]α
Afghanistan RCT AS + SP (3 + 1) 94 NR NR 94.4% 100% 100% 100% 100% 99% 76% NR NR Difference (95% CI)
Day 28: 3.3% (−2.3—9.8)
CQ (3) 96 NR NR 72.2% 97.8% 100% 100% 100% 96% 54% NR NR
Day 42: 21.1% (7.2—34.0)
Yoda et al. 2005
[26] (abstract only)
Thailand CT AS (5) + PQ (14) 42 36.7 h 14.6 h NR NR NR NR NR 95.2% NR NR NR NR
Hamedi et al.
2004 [48]α
Thailand CT AS + PQ (5 + 14) 42 36.7 h 14.6 h NR NR NR NR 100% 95.2% NR NR NR NR
Karunajeewa
et al. 2003 [49]α
Papua New Guinea CT AS (1) 5 NR NR 80% NR NR NR NR NR NR NR NR NR
Silachamroon
et al. 2003 [56]α
Thailand RCT AS (5) 157 39.3 h 21.2 h NR NR NR NR NR 47.8% NR NR NR Day 28: p < 0.0001. AS +
PQ (both) vs. AS(both)
AS (7) 159 39.6 h 21.7 h NR NR NR NR NR 52.2% NR NR NR
AS + PQ (5 + 14) 142 37.7 h 23.6 h NR NR NR NR NR 100% NR NR NR
















Table 1 Clinical trials of varying design that specifically report on the effectiveness of an artemisinin derivate combin with a blood schizonticide for the
treatment of Plasmodium vivax, P. malariae, P. ovale or P. knowlesi malaria (Continued)
Da Silva Rdo
et al. 2003 [57]β
Brazil CCT (a) AS + PQ
(1 + 7)
30 NR NR NR 96.7% NR NR NR NR NR NR NR PCT: AS faster than
CQ (p < 0.01)
(b) AS + PQ
(1 + 7)
30 NR NR NR 100% NR NR NR NR NR NR NR
(c) AS + PQ
(1 + 7)
30 NR NR NR 100% NR NR NR NR NR NR NR Cure rate: 92.3%
(group A + B + C + G) vs.
80.2% (group D + E +
F + H) P = 0.0372.
(d) AS + PQ
(1 + 5)
30 NR NR NR 100% NR NR NR NR NR NR NR
(e) AS + PQ
(1 + 5)
26 NR NR NR 96.2% NR NR NR NR NR NR NR
(f) AS + PQ
(1 + 5)
28 NR NR NR 100% NR NR NR NR NR NR NR
(g) CQ + PQ
(1 + 7)
30 NR NR NR 76.7% NR NR NR NR NR NR NR
(h) CQ+PQ (1+ 5) 30 NR NR NR 60.0% NR NR NR NR NR NR NR
Tjitra et al. 2002
[37]α
Papua, Indonesia CCT AS + SP (3 + 1) 22 1.1d 1.4d NR NR NR 100% 89.5% NR NR NR NR CQ vs. CQ + SP p = 0.046
CQ + SP(3 + 1) 6 NR NR NR NR NR NR 67% NR NR NR NR
CQ (3) 9 NR NR NR NR NR NR 11% NR NR NR NR
Phan et al. 2002
[58]α
Vietnam RCT AM (3) 113 24 h 16 h NR NR NR NR 77% NR NR NR NR Day 28: p = 0.3
CQ (3) 113 24 h 16 h NR NR NR NR 83% NR NR NR NR
Pukrittayakamee
et al. 2000 [59]α
Thailand RCT AS (5) 20 38 h 14 h NR NR NR NR 36.8% NR NR NR NR PCT:
AH (5) 20 50 h 17 h NR NR NR NR 47.0% NR NR NR NR CQ + PQ vs. AS p < 0.005
PQ (14) 30 93 h 28 h NR NR NR NR 76.9% NR NR NR NR CQ + PQ vs. QN, PQ
and SP p < 0.001
SP (1) 12 114 h 58 h NR NR NR NR 20% NR NR NR NR CQ + PQ and MQ vs.
others P < 0.017
CQ (3) 30 65 h 31 h NR NR NR NR 71.4% NR NR NR NR
QN (7) 22 98 h 31 h NR NR NR NR 35.3% NR NR NR NR
MQ (1) 20 76 h 21 h NR NR NR NR 100% NR NR NR NR
HT (1) 23 85 h 35 h NR NR NR NR 35.3% NR NR NR NR
















Table 1 Clinical trials of varying design that specifically report on the effectiveness of an artemisinin derivate combined with a blood schizonticide for the
treatment of Plasmodium vivax, P. malariae, P. ovale or P. knowlesi malaria (Continued)
Li et al., 1999
[30] NR
China NR AL (3)
(higher dose)
36 33.5 h 22.3 h NR NR NR NR NR NR NR NR NR PCT: p < 0.01
FCT: p > 0.05
AL (3)
(lower dose)
41 30.5 h 22.3 h NR NR NR NR NR NR NR NR NR Relapse rates Month 9:
84.9%, 78.8% and 22.9%
CQ + PQ (NR) 55 44.9 h 25.0 h NR NR NR NR NR NR NR NR NR
Wilairatana et al.,
1999 [60]α
Thailand CCT SP (1) 23 123.1 h 49.5 h NR NR NR NR NR 40% NR NR NR AS + PQ vs. others
P < 0.001
SP + PQ (1 + 14) 23 96.8 h 43.2 h NR NR NR NR NR 100% NR NR NR
PQ (14) 23 85.1 h 37.7 h NR NR NR NR NR 100% NR NR NR








Gabon CCT AS (3) 35 NR NR NR NR NR 100% NR NR NR 83% NR Day 7: p < 0.0001
Placebo (3) 23 NR NR NR NR NR 0% NR NR NR 0% NR Day 56: p < 0.0001
Mixed, Plasmodium ovale and/or Plasmodium malariae and/or Plasmodium falciparum
Mombo-ngoma
et al. 2012 [8]α
Gabon CT AL (3) 38 24 h NR 82% 100% NR NR NR 100% NR NR NR
Mixed infections: Plasmodium falciparum and Plasmodium vivax
Tjitra et al. 2012
[63]α
Indonesia RCT AN (1) 401 13.3 h 28.0 h NR NR NR NR NR NR 96.3% NR NR 153 (38%) P.f., 158 (39%)
P.v., 90 (22%)P.f./P.v.




Myanmar (Burma) RCT, open
label
AAQ 155 NR NR NR NR NR NR NR 92% NR NR 90.6% 129 (16%) mixed
infections P.f. and P.v.
AL 162 99.4% 98.6%
AS-MQ (fixed) 169 100% 100%
AS-MQ (loose) 161 99.4% 98.7%
















Table 1 Clinical trials of varying design that specifically report on the effectiveness of an artemisinin derivate combined with a blood schizonticide for the
treatment of Plasmodium vivax, P. malariae, P. ovale or P. knowlesi malaria (Continued)
Asley et al.
2005 [64]
Thailand RCT DHP (3) 164 <48 h <48 h NR NR NR NR NR NR NR NR 100% 45 of 499 patients (9%)
with P.v. > Results for
any malaria.
DHP (1) 169 <48 h <48 h 99.4%








NR NR Total 130 P.k. patients. 23
(18%) of P.k. patient with
follow up 26–41 days, no
recurrences.
AS-MQ 10
(i.v. AS for SM) 36
William et al.
2011 [66]
Malaysian Borneo CT AL 8 24 h NR NR NR NR NR NR NR NR NR NR NR
AS (for SM) 6 48 h
Case-series and case-reports are not depicted.
αSurvival analysis: preferred for statistical analysis of data on drug efficacy. The advantage of survival analysis is that it takes into account data on patients who were lost to follow-up or withdrawn from the study,
in particular patients with reinfection.
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parasitaemia significantly faster than CQ [43] (Table 1).
In addition, ACT also appears to reduce fever clearance
time faster than CQ (Table 1). Overall, in regions where
there is no CQ resistant P. vivax malaria, ACT is as effect-
ive as CQ at preventing recurrent parasitaemia up to day
28 [31,34-36,39,44]. Five trials [28,34-36,44] followed up
beyond day 28, but in only one, primaquine was adminis-
tered to achieve radical cure [39]. It was demonstrated
that AS + PY followed by PQ reduced the risk of recru-
descent parasitaemia between day 28 and 42 [39]. The
longest follow-up was 63 days in a study testing DHA +
PP, where DHA + PP treated patients had a 79.1% cu-
mulative risk of recurrence with P. vivax at nine weeks
(95% CI 73.5%-84.8%) in patients treated with CQ, com-
pared with 54.9% (95% CI, 48.2%-61.6%) in those receiv-
ing DHA + PP [34]. In all trials comparing ACT with
CQ, serious adverse events were rare. ACT has also
been investigated in non-randomized clinical trials with
AL [32,45-47] and injectable artesunate (for severe
P. vivax malaria) [25,26,41,42,48,49], all showing
relative short parasite and fever clearance times and
excellent day 28 cure rates.
AS + SP
Only one artemisinin combination, namely AS + SP, seems
unsuitable for the treatment of vivax malaria. Although
one non-inferiority trial [36], from Afghanistan showed
good efficacy (day 28 cure rate AS + SP 99% vs CQ 96%),
it seems that P. vivax has developed resistance to pyri-
methamine faster than P. falciparum did [67]. Conse-
quently, AS + SP may not be effective overall against
P. vivax in many regions.
ACT versus CQ + SP
Two trials investigated an ACT versus CQ + SP; one
study compared AS + SP with CQ + SP [37], and one
trial compared three artemisinin-based combinations
(DHA + PP, AL and AS + SP) with CQ + SP [38]. High
recurrence rates were noted, due to high levels of CQ
and/or SP resistance at the study site. The best form of
ACT in this trial was DHA + PP, with a day 28 cure
rate of 84.2%, significantly better than CQ + SP [38].
Only one trial evaluated the efficacy of ACT compared
to quinine [52]. The efficacy of primaquine (PQ)
against relapse was 92% (95% CI 81%-96%) for quinine
plus PQ and 98% (95% CI 91%-99%) for DHA + PP plus
PQ.
ACT versus ACT
Six studies [38,50-52,54,55,64] evaluated different
artemisinin-based combinations. Treatment efficacy with
DHA + PP was superior to AL, with higher cure rates
at day 28 [38,55]. DHA + PP was also more effectivecompared to AS + AQ [54] and AS + SP [38] while
there was no difference to AS +MQ [64] in preventing
recurrent parasitaemia. Thus, most evidence is avail-
able on the efficacy and safety of DHA + PP for the
treatment of P. vivax [28,33,34,38,50-52,54,55,68]. As
depicted in Table 1, no evidence was found on super-
iority of one regimen over others regarding the parasite
and fever clearance time.
An RCT evaluating a two versus three-day regimen of
DHA + PP (total dose 360 mg DHA and 2880 mg PP)
for uncomplicated malaria (75% P. vivax, 6,3% mixed)
showed no difference in efficacy for treatment of P. vivax
or all-species malaria before day 42 [50]. Although
piperaquine is generally well tolerated with few side
effects, there was a safety signal suggested by the degree
of QT interval prolongation. The study reported a mean
QT prolongation of 20–30 ms between pre-dose and
trough drug piperaquine levels, and roughly 18.5% of
the 80 subjects dosed had a grade I cardiac adverse
event due to QT prolongation during the 3 day period
following dosing. There were no differences in adverse
cardiac events between the two groups. More recently, a
randomized, double-blind, placebo-controlled clinical
trial of a compressed two-day regimen of DHA + PP for
malaria protective efficacy was halted after 6 weeks (69
of 231 participants enrolled) for concern over prolonged
corrected QT interval [69]. Participants received two
consecutive daily doses (total dose 360 mg DHA and
2880 mg PP) within 30 min to 3 hour of a meal. The
data was reviewed (unblinded) by the data safety mon-
itoring board and they revealed a mean QTcF pro-
longation of 46 ms over placebo at the maximum
concentration of drug in serum (Cmax) on day 2. The
authors concluded that a compressed 2-day regimen is
best avoided until the clinical relevance of these find-
ings are more thoroughly evaluated.
Evidence from trials evaluating ACT for non-falciparum
shows good efficacy of various artemisinin-based combi-
nations for mixed species infection [9,63]. In an RCT in
Myanmar (Burma) 129 (16%) of patients had a mixed spe-
cies infection, and all patients with mixed infections
responded to ACT treatment [9]. Fewer cases of P. vivax
were identified in those who received artesunate-
mefloquine than in patients who received artesunate-
amodiaquine, artemether-lumefantrine, or the loose
tablet regimen of artesunate-mefloquine [9].
Treatment of ovale and malariae malaria
Epidemiology of P. ovale and P. malariae, clinical pres-
entation and diagnosis are described in a recent review
[70] and briefly in Additional file 3. Only three trials
evaluating an artemisinin derivative for P. ovale or P.
malariae could be identified [8,61,62]. A clinical study
evaluated the efficacy and tolerability of a three-day
Visser et al. Malaria Journal 2014, 13:463 Page 11 of 18
http://www.malariajournal.com/content/13/1/463course of artesunate monotherapy for the clearance of
asymptomatic P. malariae infections in Gabon [62].
Patients were randomized and received artesunate (n = 63)
or placebo (n = 45). Most were mixed infections with
P. falciparum and 18 were asymptomatic P. malariae
mono-infections. On day 7, the cure rate was 100%
(95% CI 91-100%) for P. malariae patients treated with
artesunate versus no cure (95% CI 0-15%) in the placebo
group. Treatment with artesunate led to a parasito-
logical cure rate of 83% by day 56 in this semi-immune
population. However, there may have been possible
re-infections during the 56-day follow-up period. The
true cure rate is likely to be underestimated as these
results were not corrected for by PCR. In another clinical
trial, artesunate was 100% effective for the treatment of
P. ovale infections, with a PCT and FCT of < 48 hours
[61]. Treatment was well tolerated and serious adverse
events were not reported. Another study in Gabon, a
prospective non-randomized trial evaluated the safety and
efficacy of an ACT (AL) for non-falciparum malaria [8].
Most patients in this study had a mixed infection (n = 32)
and 7 patients presented with a non-falciparum mono-
infection. The median parasite clearance time was
36 hours, median FCT 8 hours, and all patients had an
adequate clinical and parasitological response at day
28 (95% CI 91-100%). No serious adverse events were
recorded. The limitations of this study were its non-
randomized design, short follow-up period of 28 days
(likely to miss any relapse of P. ovale) and no anti-
relapse therapy with primaquine administered for
P. ovale. One other case report is available, which
reported good efficacy of intravenous artesunate for
mixed P. falciparum/P. malariae infection [71]. This
stands in contrast to a case report from Italy, in which
they described a mixed P. falciparum/P. malariae
infection in a HIV-infected male and ineffectiveness
of artemether/lumefantrine to clear the infection of
P. malariae [72]. This could be explained by the inef-
fectiveness of AL against the long-lasting schizogonic
pre-erythrocytic phase of P. malariae or a natural induced
drug resistance of the parasite, which have never been
published before in quartan malaria. However, single
case reports leave open questions, and hypotheses on
lack of ACT efficacy against P. malariae remain to be
somewhat weak.
Treatment of Plasmodium knowlesi malaria
A detailed overview on the history, clinical symptoms and
diagnosis of P. knowlesi malaria is provided in a recent
review [73]. Because experience is limited to low case
numbers, and as there are no high-quality clinical studies
with adequate patient numbers for understandable rea-
sons, current WHO Malaria Treatment Guidelines (2010)
[16] do not provide official treatment recommendationsyet for uncomplicated knowlesi malaria. For severe
knowlesi malaria, WHO recommends intravenous arte-
sunate [74] in their practical handbook ‘Management
of severe malaria (2013). Taking into account the biol-
ogy of the parasite and the resulting clinical features
with possible rapid progress to severe disease, ACT
appear as a natural choice for first-line treatment.
Consequently, hospital guidelines in endemic areas
currently recommend an oral ACT (AL) for non-severe
P. knowlesi malaria, and intravenous artesunate for
severe knowlesi malaria [46]. A recent study from Barber
and colleagues confirmed the safety and efficacy of AL
(n = 109) or artesunate-mefloquine (n = 10) for uncom-
plicated P. knowlesi infections in humans [46]. The
mean parasite clearance time (not separated for P. vivax
or P. knowlesi), was two days, with 55/119 (42%) of
P. knowlesi infected patients being smear-negative by
day 1 (P = 0.032). The median fever clearance time
was one day in P. knowlesi compared to two days for
P. falciparum malaria. Twenty-three (18%) P. knowlesi
patients were followed up during days 26–41, with no
recrudescence identified. For severe knowlesi malaria,
intravenous artesunate was successfully used. In this
study, >80% (15 of 18) of the patients with a P. knowlesi
parasitaemia >100,000 parasites/μL met other severity
criteria, supporting the use of this cut-off value for
mandating intravenous artesunate. William and col-
leagues demonstrated excellent efficacy of AL (n = 8) for
uncomplicated knowlesi malaria in a retrospective case
review study [66]. The median parasite clearance time
was significantly shorter for patients receiving AL (one
day; range 0–3) and for those receiving CQ (2.5 days;
range 1–3) or quinine (2.5 days; range 1–3) (p = 0.01)
[66]. Of the 22 patients with severe P. knowlesi malaria,
16 were treated with intravenous quinine, six received
intravenous artesunate. The median PCT was signifi-
cantly shorter with artesunate (2 days; range 1–3) than
with quinine (4 days; range 2–7) (p = 0.02). Six patients
died, of which 5 had been administered quinine (median
severity criteria 2; case-fatality rate 31%), and 1 was given
artesunate (median severity criteria 2.5; case-fatality rate
16.6%). Only a few others report on the treatment of
P. knowlesi with ACT. A patient from Pahang Province
(Malaysia) was unsuccessfully treated with mefloquine,
but recovered with intravenous quinine in combination
with artemether-lumefantrine [75]. Another case report
describes a case of P. knowlesi infection in a traveller from
Thailand in Germany. Parenteral treatment was started
(2.4 mg/kg) and the patient was switched to oral AL the
next day, on which she fully recovered [76].
Discussion
Evidence for the efficacy of ACTs for P. falciparum malaria
is extensive, and rapidly growing for P. vivax malaria.
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knowlesi are much scarcer and limited to non-randomized
studies, case-series or case-reports.
Plasmodium vivax malaria
Several artemisinin-based combinations yield high effica-
cies against P. vivax parasites, both sensitive and resist-
ant to CQ. Studies identified in this review showed good
efficacy of ACT against the blood stages of P. vivax, with
quicker parasite and fever clearance times compared to
CQ monotherapy. Countries with CQ-resistant P. vivax
are already implementing a unified ACT-based treat-
ment policy [77,78]. Increasing resistance of chloroquine
against P. vivax is, after the first report in 1989 from
Papua New Guinea [79], reported in Indonesia [80-83],
Myanmar [84], Papua New Guinea [85], Vietnam [86],
Turkey [87,88], Colombia [89], Brazil [90], Brazilian
Amazon [91] and Ethiopia [29,92-94]. A recent system-
atic review and meta-analysis reviewed P. vivax malaria
treatment efficacy studies to establish the global extent
of chloroquine resistance [15]. Although there was
substantial heterogeneity of study design and analysis
between the 129 eligible clinical studies (21,694 patients)
chloroquine resistance was present in 58 (53%) of 113
assessable study sites, spread across most countries that
are endemic for P. vivax. Also, within countries close
to elimination of malaria, an increasing proportion of
P. vivax malaria is imported and, outside sub-Saharan
Africa, the proportions of all cases caused by P. vivax
are rising [95]. In travellers returning from supposedly
CQ-sensitive P. vivax to non-endemic areas, the best
treatment remains to be elucidated; in these cases, the
economic, malariometric, and operational costs of ACT
versus CQ need to be weighted by the clinician. Different
regimens are still acceptable if diagnostic tests reliably
differentiate CQ-resistant P. falciparum from P. vivax.
However, this is even in experienced laboratories not
always the case. Moreover, the paradigm among infec-
tious diseases experts that bacterial infections should be
treated as “narrow as possible” does not apply to treating
malarial infections. Monotherapy for malaria will only
increase the likelihood of resistance, in contrast with
narrowing down antibiotic therapy resulting in lower
levels of bacterial resistance [96].
A position paper (2012) from the European Society for
Clinical Microbiology and Infectious Diseases, summa-
rized main issues regarding the management of imported
malaria [97]. For the treatment of non-falciparum malaria,
they recommended chloroquine as the drug of choice
and ACT a pragmatic alternative (especially in case of
chloroquine resistance). Currently, one trial is recruit-
ing patients to evaluate the efficacy, safety and tolerabil-
ity of DHA + PP (3 days) with imported P. vivax malaria
(NCT02110784).So far, the use of ACT for non-falciparum malaria, in
particular P. vivax, has been jeopardized by the sup-
posedly higher economic costs [98]. This judgement is
based on assumption rather than evidence and ignores
the malariometric advantages of ACT, declining costs and
practical, organizational advantages of a unified ACT-
based regimen. Studies evaluating the cost-effectiveness of
ACT-based strategy for non-falciparum malaria should be
conducted.
The use of ACT for non-complicated non-falciparum
malaria infection is convenient but may imply the risks’
of a higher utilization of the combination drug, with two
possible drawbacks. Firstly, the availability of good qual-
ity drugs may be limited in malaria endemic countries
[99]; however, there are important caveats to accurately
estimate the prevalence and distribution of poor quality
anti-malaria drugs. Secondly, inadequate use of ACT
(ACT is more expensive than chloroquine) by the popu-
lation in resource-challenged settings can possibly lead
to resistance to both P. falciparum and non-falciparum
strains [100].
In contrast to P. falciparum malaria, P. vivax, and to a
lesser extent P. ovale, form hypnozoites, which remain
dormant in liver cells after an acute infection. Therefore,
in P. vivax infections (and also P. ovale) the removal of
blood schizonts is not sufficient to clear the infection, as
the eradication of hypnozoites (“radical cure”) is required
to prevent relapses. This is clinically important and
cost-effective particularly in travellers who are not likely
to be re-infected.
ACT does not affect the hypnozoites in the liver, but
ACT with a long half-live partner drug, such as pipera-
quine 23–28 days [101], (compared to CQ 1–2 months
[102]) was demonstrated to better prevent recurrent
parasitaemia after day 28 [34,36,39]¸ up to day 42 [38,55]
and 63 [34]. AL which has a short half-life, although less
susceptible to the appearance of resistant parasites, is
associated with a shorter time to P. vivax recurrent
parasitaemia. However, neither ACT nor CQ is active
against P. vivax hypnozoites and thus the treatment
must be combined with primaquine, currently the only
approved drug able to achieve radical cure. WHO
guidelines recommend a course of primaquine for the
radical treatment of P. vivax of at least 14 days [16].
Although not yet marketed and currently under devel-
opment, tafenoquine (8-aminoquinoline drug) could
lead to a game change in treatment and it may be super-
ior to current treatment due to its radical cure capacity.
The proposed indication for tafenoquine is the clear-
ance of the hypnozoite stages of P. vivax and P. ovale. The
assessment of the prophylactic activity and pharmacoki-
netic profile of oral tafenoquine compared to primaquine
for inhibition of liver stage malaria infections demon-
strated a much improved efficacy of tafenoquine when
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study comparing single-dose tafenoquine 300 mg co-
administered with CQ for P. vivax malaria relapse pre-
vention was more efficacious than CQ alone, with a
similar safety profile [104].
Plasmodium ovale and Plasmodium malariae malaria
At present, P. ovale and P. malariae are among the most
neglected tropical diseases, particularly in sub-Saharan
Africa. This is illustrated by the fact that only three
clinical trials [8,61,62] were published on ACT for
P. ovale and P. malariae malaria, compared to a wealth
of clinical trials on ACT for P. falciparum malaria
[105]. More evidence on the efficacy and safety of ACT
in the treatment of P. ovale and P. malariae is essential
before further discouraging the current use of CQ for
non-falciparum malaria. Today, the limited evidence
available supports both the use of CQ as well as ACT
(AL) for P. ovale and P. malariae. It is advisable to
treat with ACT if species classification is not 100%
certain, because P. ovale and P. malariae often occur
in mixed infections with P. falciparum, which is likely
to be CQ-resistant [8]. Keeping in mind that beyond
in vivo testing; in vitro and in silico methods to assess
drug resistance of non-falciparum species remain very
much limited up to date. P. ovale and P. malariae are
considered sensitive to CQ. However, there is one
report on CQ-resistant P. malariae from South Sumatra,
Indonesia [17]. Simultaneous use of two anti-malarials
of different modes of action (as with ACT) will reduce
the chance of selection of a resistant strain [96]. Of con-
cern are the results of a trial conducted in Ghanaian
schoolchildren, where individuals with microscopically
confirmed asymptomatic malaria were treated with
dihydroartemisinin-piperaquine and followed for three
weeks [106]. A persistent detection of P. malariae, P. ovale
curtisi and P. ovale wallikeri was observed. This apparent
“treatment failure” requires more investigation. It is import-
ant to note, however, that in vivo anti-malarial drug efficacy
cannot really be determined from data derived from out-
comes of asymptomatic infections. Furthermore, their
method of measurement of outcome, PCR, is not yet
validated as a primary endpoint method for anti-
malarial drug trials. It is speculated by the authors that
a relapse of P. ovale could explain the persistent detec-
tion of parasites; however, the prophylactic effect of
piperaquine which is generally assumed to last more
than three weeks makes this less plausible [106].
Furthermore, it is possible that only gametocytes of
P. malariae and P. ovale were detected by PCR, and not
the asexual stages, as it is known for P. falciparum that
gametocyte carriage following a dihydroartemisinin-
piperaquine regimen is more frequent than for other
artemisinin-based combinations (e.g. AL) [107]. In P.malariae, the long intra-erythrocytic cycle of three days
may explain their persistence due to dihydroartemisinin
short Tmax (±2 h) and rapid clearance by CYP3A4/5 in
the liver, and, therefore, may be more likely to survive
after each dose of artemisinin. Similar observations have
been made concerning delayed parasite clearance times
in P. malariae in Madagascar, where a patient treated
with CQ was still positive for P. malariae (detected by
PCR) on day 7, although it was subsequently cleared
with no late recurrence [108]. Another study, with CQ
for P. malariae, showed a significant lower clinical
response rate, with nearly 20% of patients still parasitae-
mic by day 2 and one patient remaining parasitaemic on
day 4 [109]. CQ’s marked stage specificity of action may
account for reports of delayed parasite clearance times
[109]. Although highly desirable, randomized controlled
trials testing different formulations of ACT versus CQ
in the treatment of P. ovale and P. malariae mono-
infections are difficult to realize due to patient’s safety
issues; misdiagnosis of P. falciparum malaria can have
fatal consequences.
Plasmodium knowlesi malaria
Although currently randomized clinical trials on the
treatment of P. knowlesi are lacking, several studies have
demonstrated the efficacy and safety of ACT (particu-
larly AL) [65,66]. Although CQ is efficacious (and cheap)
for non-severe P. knowlesi malaria, it is recommended,
in view of the potential severity and velocity at which
the disease can develop, to use an ACT that is suited for
the treatment of P. falciparum or P. malariae for uncom-
plicated P. knowlesi malaria. This is particularly relevant
for elderly patients because they are at greater risk of
severe disease due to the strong correlation between age
and parasite count [46,110,111]. The faster parasite clear-
ance properties of AL are more likely to prevent the most
common complication of severe knowlesi malaria; hyper-
parasitaemia [46]. The importance of early diagnosis [112]
and rapid treatment is underlined by the fact that parasite
biomass is the major independent risk factor for severe
knowlesi malaria [46]. Parenteral artesunate, which
is associated with short parasite clearance times, is
apparently preferable as treatment of severe knowlesi
malaria [46] as it is for falciparum malaria.
In studies conducted in Sarawak, it was demonstrated
that whilst most patients with microscopy-diagnosed
P. malariae infection harboured P. knowlesi; approxi-
mately 10% were actually infected with P. falciparum
[113]. In travellers returning from Malaysia and other
P. knowlesi endemic areas, with a high prevalence of
CQ-resistant falciparum malaria, negligent use of CQ
for misdiagnosed P. falciparum malaria may have detri-
mental consequences. Also, resistance of P. knowlesi to
anti-malarial drugs have not been observed yet [114].
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over quinine in terms of not requiring rate-controlled
infusion or cardiac monitoring [16]. Plasmodium knowlesi
was responsible for almost half of the malaria deaths in
Sabah (Borneo), due to misdiagnosis with P. malariae
and delayed administration of artesunate for severe
non-falciparum malaria [115]. In a retrospective study,
parasite clearance time of AL and injectable artesunate,
compared to CQ and quinine, was faster, with fewer deaths
with artesunate than quinine [66]. More trials are needed
and currently two trials are initiated: “ACT KNOW”
(Clinicaltrials.gov: NCT01708876 [116]), a RCT to test
whether fixed combination of artesunate-mefloquine is
superior to CQ and “CAN KNOW” (NCT02001012), a
RCT to test whether AL is superior to CQ.
Conclusions
The considerable burden of non-falciparum malaria
(predominantly P. vivax) in endemic areas and among
travellers, the clear recognition as non-benign infection
and the emergence of CQ-resistant strains call for a
paradigm change in the way non-falciparum malaria
infections are treated. Although non-falciparum malaria
remains susceptible to CQ in parts of the world, the role
of ACT in the treatment of non-falciparum malaria in
endemic as well as non-endemic areas should be
acknowledged. ‘Even’ if most non-falciparum infections
do not take a potentially life-threatening course, the
shorter parasite and fever clearance times alone make a
strong case for ACT following establishment of the
correct diagnosis. A more uniform treatment for malaria
would offer important organizational, logistical and
economic advantages, next to malariologic advantages of
ACT in preventing resistance, showing rapid parasite
and fever clearance times and good cure rates. However,
the incomplete nature of current data on the efficacy
of ACT in the treatment of P. ovale, P. malariae and
P. knowlesi in endemic areas but also as imported condi-
tions compels current malaria researchers to evaluate
the efficacy, safety and cost-effectiveness of these drugs
in randomized controlled clinical trials. Because most
studies have been carried out in endemic settings, one
must be careful transferring these results directly to
non-immune travellers with imported non-falciparum
malaria. On the other hand, European treatment guide-
lines are mainly based on data from studies carried out
in endemic areas, since there is a paucity of original
prospective treatment data for non-immune patients
[21]. It must be acknowledged that in most settings,
there are too few participants for large-scale trials asses-
sing ‘one size fits it all’ strategies for non-falciparum
malaria in and outside endemic areas. Therefore, the
publication of observational data derived from mouse
models, pharmacokinetic data from clinical trials shouldbe encouraged. Studies evaluating the cost-effectiveness
of ACT-based strategy for non-falciparum malaria
should be conducted [117].
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